| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10226436 | NEVAKAR INJECTABLES | Norepinephrine compositions and methods therefor |
Jan, 2038
(14 years from now) | |
| US11413259 | NEVAKAR INJECTABLES | Norepinephrine compositions and methods therefor |
Jan, 2038
(14 years from now) | |
| US10420735 | NEVAKAR INJECTABLES | Norepinephrine compositions and methods therefor |
Jan, 2038
(14 years from now) | |
| US11602508 | NEVAKAR INJECTABLES | Norepinephrine compositions and methods therefor |
Jan, 2038
(14 years from now) | |
| US10159657 | NEVAKAR INJECTABLES | Norepinephrine compositions and methods therefor |
Jan, 2038
(14 years from now) | |
| US10568850 | NEVAKAR INJECTABLES | Norepinephrine compositions and methods therefor |
Jan, 2038
(14 years from now) | |
Norepinephrine Bitartrate In 0.9% Sodium Chloride is owned by Nevakar Injectables.
Norepinephrine Bitartrate In 0.9% Sodium Chloride contains Norepinephrine Bitartrate.
Norepinephrine Bitartrate In 0.9% Sodium Chloride has a total of 6 drug patents out of which 0 drug patents have expired.
Norepinephrine Bitartrate In 0.9% Sodium Chloride was authorised for market use on 06 October, 2022.
Norepinephrine Bitartrate In 0.9% Sodium Chloride is available in solution;intravenous dosage forms.
Norepinephrine Bitartrate In 0.9% Sodium Chloride can be used as indicated to raise blood pressure in adult patients with severe, acute hypotension.
The generics of Norepinephrine Bitartrate In 0.9% Sodium Chloride are possible to be released after 30 January, 2038.
Drugs and Companies using NOREPINEPHRINE BITARTRATE ingredient
Market Authorisation Date: 06 October, 2022
Treatment: Indicated to raise blood pressure in adult patients with severe, acute hypotension
Dosage: SOLUTION;INTRAVENOUS
NOREPINEPHRINE BITARTRATE IN 0.9% SODIUM CHLORIDE family patents
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10888534 | INFORLIFE | Storage stable ready-to-use norepinephrine aqueous solutions in flexible plastic bags |
Apr, 2039
(15 years from now) | |
Norepinephrine Bitartrate In 0.9% Sodium Chloride is owned by Inforlife.
Norepinephrine Bitartrate In 0.9% Sodium Chloride contains Norepinephrine Bitartrate.
Norepinephrine Bitartrate In 0.9% Sodium Chloride has a total of 1 drug patent out of which 0 drug patents have expired.
Norepinephrine Bitartrate In 0.9% Sodium Chloride was authorised for market use on 15 September, 2022.
Norepinephrine Bitartrate In 0.9% Sodium Chloride is available in solution;intravenous dosage forms.
The generics of Norepinephrine Bitartrate In 0.9% Sodium Chloride are possible to be released after 26 April, 2039.
Drugs and Companies using NOREPINEPHRINE BITARTRATE ingredient
Market Authorisation Date: 15 September, 2022
Treatment: NA
Dosage: SOLUTION;INTRAVENOUS
NOREPINEPHRINE BITARTRATE IN 0.9% SODIUM CHLORIDE family patents
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic